Seattle genetics to host conference call and webcast discussion of first quarter financial results on april 27, 2017

Bothell, wash.--(business wire)--seattle genetics, inc. (nasdaq: sgen) announced today that it will report its first quarter financial results on thursday, april 27, 2017, after the close of financial markets. following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. access to the event can be obtained as follows: live access on thursday, april 27, 2017 1:30 p.m. pacific time / 4:30 p.m. eastern time telephone 888-283-6901 (domestic) or 719-325-2217 (international); conference id 8468596 webcast available at www.seattlegenetics.com in the investors and news section replay access telephone replay will be available beginning at approximately 4:30 p.m. pt on thursday, april 27, 2017, through 5:00 p.m. pt on monday, may 1, 2017, by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference id 8468596 webcast replay will be available on the seattle genetics website at www.seattlegenetics.com in the investors and news section about seattle genetics seattle genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. the company’s industry-leading antibody-drug conjugate (adc) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. adcetris® (brentuximab vedotin), the company’s lead product, in collaboration with takeda pharmaceutical company limited, is the first in a new class of adcs commercially available globally in 66 countries for relapsed classical hodgkin lymphoma (hl) and relapsed systemic anaplastic large cell lymphoma (salcl). seattle genetics is also advancing vadastuximab talirine (sgn-cd33a; 33a), an adc in a phase 3 trial for acute myeloid leukemia. headquartered in bothell, washington, seattle genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. the company has collaborations for its proprietary adc technology with a number of companies including abbvie, astellas, bayer, celldex, genentech, glaxosmithkline and pfizer. more information can be found at www.seattlegenetics.com.
SGEN Ratings Summary
SGEN Quant Ranking